PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。

Progenics Pharmaceuticals, Inc.

One World Trade Center
47th Floor Suite J
New York City, NY 10007
United States
646-975-2500
http://www.progenics.com

界別Healthcare
行業Biotechnology
全職員工79

高階主管

名稱標題支付行使價出生年份
Mr. Mark R. BakerCEO & Director939.35k1955
Mr. Patrick FabbioExec. VP & CFO536.64k1968
Mr. Benedict OsorioChief Operating Officer506.27k1957
Dr. Vivien WongExec. VP of Devel.580.21k1957
Mr. Bryce V. TenbargeSr. VP of Commercial519.05k1973
截止 2018年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

公司管治

截至 2019年4月1日 止,Progenics Pharmaceuticals, Inc. 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中:2;董事會:4;股東權利:1;現金賠償:6。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。